For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Visual guides › Mechanism diagram

How GLP-1 receptor agonists work

One hormone, three effects, and the one place a woman's physiology enters the picture.

Mechanism diagram · 4 min read

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after a meal. The drugs in this class, including semaglutide and tirzepatide, are engineered to imitate it and resist being broken down as quickly. The diagram traces what that imitation does.

GLP-1 receptor agonistmimics the gut hormone GLP-1PancreasGlucose-dependentinsulin release ↑BrainSatiety signal;appetite reducedStomachGastric emptyingslowedFEMALE-SPECIFIC INTERACTIONSlowed emptying can reduce absorption of oralcontraceptives, documented for tirzepatide.
A GLP-1 receptor agonist mimics the gut hormone GLP-1, producing three main effects. The slowed gastric emptying (right) is also the source of the one well-documented female-specific interaction.

The three effects

  • Pancreas, the drug enhances insulin release, but only when blood glucose is elevated (glucose-dependent), which is why it lowers glucose without the same low-blood-sugar risk as some other agents.
  • Brain, it acts on appetite centers to increase satiety, the feeling of fullness.
  • Stomach, it slows gastric emptying, the rate at which the stomach hands food to the small intestine.

Where female physiology enters

That third effect has a female-specific consequence. Because the stomach empties more slowly, an oral contraceptive pill can be absorbed more slowly and less completely. For tirzepatide, the approved labeling advises using a backup or non-oral method of contraception for a window after starting the drug and after each dose increase. This is a documented, label-level interaction, not an extrapolation.

The same slowed gastric emptying that drives satiety can also reduce oral-contraceptive absorption, a documented, female-specific interaction for tirzepatide.
What this diagram is not

This is a mechanism sketch, not medical advice or a reason to start or stop anything. Whether a GLP-1 drug is appropriate, and how contraception should be handled around it, is a conversation for a clinician and pharmacist who know your history.

For the fuller breakdown of what the trials did and didn't establish for women, including the cycle-phase questions that remain unstudied, see the article GLP-1s and the menstrual cycle.

Compounds referenced

SemaglutideA
Semaglutide: of 5,189 PubMed records, 1,116 are tagged as including female subjects and 14 carry a sex-analysis tag.
TirzepatideA
Tirzepatide: of 2,288 PubMed records, 443 are tagged as including female subjects and 5 carry a sex-analysis tag.
RetatrutideB
Retatrutide: of 158 PubMed records, 20 are tagged as including female subjects and 2 carry a sex-analysis tag.

Ready to take the next step?

Now that you've seen what the evidence does and doesn't say, find research-grade material from our verified supplier, or ask Vera for a sourced answer on any compound.

Shop research peptides ↗Ask VeraBrowse the database

Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Sources

  1. MOUNJARO (tirzepatide) U.S. Prescribing Information, oral hormonal contraceptive interaction and barrier-method advisory for 4 weeks after initiation and each dose escalation. View source ↗
  2. Prescribing information for semaglutide; review literature on GLP-1 physiology (insulin secretion, satiety, gastric emptying).

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe. Some outbound links are affiliate links.